Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy

Clinical Infectious Diseases

Volumn 46, Issue 12, 2008, Pages

  Wolter, Daniel J ^a   Acquazzino, Dee ^b   Goering, Richard V ^a   Sammut, Paul ^b   Khalaf, Noha ^a   Hanson, Nancy D ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CARBAPENEM; CEFTAZIDIME; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PORIN; RNA; TOBRAMYCIN; ANTIINFECTIVE AGENT; BACTERIAL DNA; CARBAPENEM DERIVATIVE; OPRD PROTEIN, PSEUDOMONAS AERUGINOSA;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CYSTIC FIBROSIS; DNA TEMPLATE; DRUG SENSITIVITY; GENE AMPLIFICATION; GENE EXPRESSION; GENE SEGREGATION; GENE SEQUENCE; GRAM NEGATIVE INFECTION; HUMAN; LUNG FUNCTION TEST; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; CASE REPORT; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; SPUTUM; TRANSPOSON;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; CYSTIC FIBROSIS; DNA TRANSPOSABLE ELEMENTS; DNA, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PORINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM;

EID: 46249124312     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/588484     Document Type: Article

References (28)

1. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60:539-74.
2. Jalal S, Ciofu O, Hoiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2000; 44:710-2.
3. Vogne C, Aires JR, Bailly C, Hocquet D, Plesiat P. Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004; 48:1676-80.
4. Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 2006; 103:8487-92.
5. Ciofu O, Riis B, Pressler T, Poulsen HE, Hoiby N. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother 2005; 49:2276-82.
6. Hall LM, Henderson-Begg SK. Hypermutable bacteria isolated from humans - a critical analysis. Microbiology 2006; 152:2505-14.
7. Macia MD, Blanquer D, Togores B, Sauleda J, Perez JL, Oliver A. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 2005; 49:3382-6.
8. Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999; 43:424-7.
9. Wolter DJ, Hanson ND, Lister PD. Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance. FEMS Microbiol Lett 2004; 236:137-43.
10. Pirnay JP, De Vos D, Mossialos D, Vanderkelen A, Cornelis P, Zizi M. Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates. Environ Microbiol 2002; 4:872-82.
11. Kohler T, Epp SF, Curty LK, Pechere JC. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 1999; 181:6300-5.
12. Sobel ML, Neshat S, Poole K. Mutations in PA2491 (mexS) promote MexT-dependent mexEF-oprN expression and multidrug resistance in a clinical strain of Pseudomonas aeruginosa. J Bacteriol 2005; 187:1246-53.
13. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 6th ed. CLSI document M7-A6. Wayne, PA: CLSI, 2003.
14. Goering RV. Pulsed-field gel electrophoresis. In: Persing DH, Tenover FC, Versalovic J, et al., eds. Molecular microbiology: diagnostic principles and practice. Washington, DC: ASM Press, 2004:185-96.
15. Wolter DJ, Hanson ND, Lister PD. AmpC and OprD are not involved in the mechanism of imipenem hypersusceptibility among Pseudomonas aeruginosa isolates overexpressing the mexCD-oprJ efflux pump. Antimicrob Agents Chemother 2005; 49:4763-6.
16. Macia MD, Borrell N, Perez JL, Oliver A. Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion. Antimicrob Agents Chemother 2004; 48:2665-72.
17. Polgar G, Promadhat V. Pulmonary function testing in children: techniques and standards. Philadelphia, PA: WB Saunders, 1971.
18. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005; 293:581-8.
19. Parad RB, Gerard CJ, Zurakowski D, Nichols DP, Pier GB. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun 1999; 67:4744-50.
20. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006; 73:27-33.
21. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288:1251-4.
22. Simpson W, Wang CY, Mikolajczyk-Pawlinska J, et al. Transposition of the endogenous insertion sequence element IS1126 modulates gingipain expression in Porphyromonas gingivalis. Infect Immun 1999; 67:5012-20.
23. Kondo K, Horinouchi S. A new insertion sequence IS1452 from Acetobacter pasteurianus. Microbiology 1997; 143:539-46.
24. Kresse AU, Blocker H, Romling U. ISPa20 advances the individual evolution of Pseudomonas aeruginosa clone C subclone C13 strains isolated from cystic fibrosis patients by insertional mutagenesis and genomic rearrangements. Arch Microbiol 2006; 185:245-54.
25. Kohler T, Michea-Hamzehpour M, Plesiat P, Kahr AL, Pechere JC. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997; 41:2540-3.
26. Le Thomas I, Couetdic G, Clermont O, Brahimi N, Plesiat P, Bingen E. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. J Antimicrob Chemother 2001; 48:553-5.
27. Wolter DJ, Black JA, Acquazzino D, Goering RV, Sammut P, Hanson ND. Emergence of fluoroquinolone resistant Pseudomonas aeruginosa in a cystic fibrosis patient: discordance between MexEF-OprN and carbapenem susceptibility [abstract C1-2063]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003:97.
28. Kohler T, Kok M, Michea-Hamzehpour M, et al. Multidrug efflux in intrinsic resistance to trimethoprim and sulfamethoxazole in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40:2288-90. e142-e145